Latest Conference Articles

The addition of ublituximab and umbralisib (Ukoniq; U2) to ibrutinib (Imbruvica) demonstrated a 77% undetectable minimal residual disease (uMRD) rate in patients with chronic lymphocytic leukemia.

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses third-line treatment options for patients with diffuse large b-cell lymphoma.

Point-of-use shower filtration may be an effective strategy in reducing waterborne pathogens and protecting patients who underwent stem cell transplant from infection.

A patient-friendly stoplight tool with 3 different colored zones helped patients undergoing chemotherapy manage diarrhea and reduce hospital and emergency department visits.

Patients who receive medical cannabis in addition to standard opioids may require less overall opioid treatment to manage their pain.

Specialty nurse practitioners can help tailor pain management programs for patients with sickle cell disease and decrease hospital stay times.

Independent verification of documentation is paramount to patient safety.

The framework for establishing equity, diversity, and inclusion throughout oncology nursing already exists within the standard for health and safety, explains Aliènne Salleroli, MS, BSN, RN, OCN.

An implementation of nursing practice changes helped improve the fall rates among patients being treated by the surgical oncology team.

Oncology nurses found that the use of a flexible catheter for subcutaneous immunotherapy is linked with increased safety and satisfaction.

Very low dose radiation therapy was found to be an effective treatment approach in the palliative setting for patients with indolent non-Hodgkin lymphoma.

Michelle Mollica, PhD, MPH, RN, OCN, of the National Cancer Institute, discusses how childhood cancer survivors may face different challenges than adult or geriatric patients.

Ilene Galinsky, BSN, MSN, ANP-C, senior leukemia protocol research nurse practitioner, at Dana Farber Cancer Institute, discusses how treatment for patients with acute myeloid leukemia has evolved in recent years.

Oncology nurses are in less control of their communication environment compared with other health care providers; however, certain strategies can help them communicate effectively with their patients.

At the 47th Annual ONS Congress, CURE® Media group honored oncology nurses at their 2022 Extraordinary Healer® Award ceremony.

The most important thing that an oncology nurse can do to help a patient navigate their sexual health is repeatedly offer them permission to have conversations surrounding their health.

Patients with relapsed/refractory large B-cell lymphoma continued to derive benefit from lisocabtagene maraleucel after 2 years of follow-up.

Patients with relapsed or refractory large B-cell lymphoma experienced improved overall survival following treatment with axicabtagene ciloleucel.

Belimumab has emerged as a safe and tolerable agent that may be useful for the prophylaxis of chronic graft-vs-host-disease.

The CD40 agonist sotigalimab in combination with pembrolizumab yielded promising outcomes in patients with unresectable stage III or IV metastatic melanoma.

Ivosidenib maintains quality of life in cholangiocarcinoma, immunotherapy outperforms chemotherapy in select gastric/gastroesophageal junction adenocarcinoma, and nivolumab induces high response rates are observed among patients with BRAF V600E–mutant metastatic colorectal cancer.

Preliminary findings from the phase 1/2a TEM-GBM study highlight the potential utility of temferon, genetically modified Tie2-expressing monocytes targeting interferon a2 in treating patients with glioblastoma.

Longer follow-up data from the phase 1/2 CodeBreaK 100 trial show that patients with KRAS G12C–mutant non–small cell lung cancer experienced improved prolonged overall survival and encouraging response rates with sotorasib.

TTX-030 is the first fully human IgG4 antibody designed to target CD39, as well as the first CD39 inhibitor to undergo a phase 1 clinical trial.

Patients with YAP1 and inflamed T-cell expressing extensive-stage small cell lung cancer experienced superior overall survival following treatment with durvalumab and etoposide.

Patients with heavily pretreated lymphoma experienced promising clinical responses following treatment with the innate cell engager AMF13 plus preactivated and expanded natural killers (NK) cells.

Data collected with patient-reported outcomes show that pembrolizumab, with or without bevacizumab, is associated with a favorable toxicity profile in effectively treating women with persistent, recurrent, or metastatic cervical cancer.

Whether administered as an immune primer or concurrently with extended field chemoradiation, atezolizumab demonstrated efficacy in triggering T-cell clonal expansions and prolonging progression-free survival in patients with cervical cancer.